Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center

Articles

Therapeutic Advances in Prophylaxis Against CIN

December 3rd 2021

An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.

CIN: Adopting SIMBA Therapy Into Clinical Practice

December 3rd 2021

A panel of oncologists react to their interest in using plinabulin as prophylaxis against chemotherapy-induced neutropenia in future clinical practice.

CIN: Implications of the PROTECTIVE-2 Study

November 29th 2021

Implications for treating patients with solid tumor cancers with plinabulin based on quality-of-life data and results demonstrated by the PROTECTIVE-2 trial.

Potential Dosing Strategies to Mitigate CIN

November 12th 2021

Considerations regarding the potential to prevent chemotherapy-induced neutropenia with newer therapeutic strategies as well as changes to treatment dosages.

CIN Prophylaxis and Bone Pain

November 12th 2021

Recommendations regarding how to best manage patients who experience bone pain from chemotherapy-induced neutropenia prophylaxis with growth factor support.

Anticancer Therapy: Safety vs Efficacy

November 5th 2021

Breast oncologists discuss how they weigh the efficacy of anticancer treatment with the possibility of a treatment-related adverse event, like chemotherapy-induced neutropenia.

Managing CIN in Patients With Breast Cancer

November 5th 2021

Preventive therapies and factors that impact how to best mitigate chemotherapy-induced neutropenia in patients with breast cancer.

Managing Chemotherapy-Induced Neutropenia With G-CSFs

October 29th 2021

Recommendations for intervening with growth factor support and important considerations for reducing or discontinuing anti-cancer therapy when patients show signs of neutropenia.

CIN Prophylaxis: Treating With G-CSFs

October 29th 2021

Advantages, in terms of safety and efficacy, of granulocyte colony-stimulating factors used as prophylaxis against chemotherapy-induced neutropenia.

G-CSFs for Chemotherapy-Induced Neutropenia

October 22nd 2021

Breast oncologists react to the availability of granulocyte colony-stimulating factors, used as prophylaxis against chemotherapy-induced neutropenia.

CIN Prophylaxis: When to Intervene

October 22nd 2021

Variables that oncologists should consider when determining when to initiate prophylactic therapy for chemotherapy-induced neutropenia in patients with breast cancer.

Consequences of Chemotherapy-Induced Neutropenia

October 22nd 2021

A panel of breast oncologists define chemotherapy-induced neutropenia in terms of how they assess risk and attempt to prevent treatment-related toxicities in patients with cancer.

Rapid Readouts: Phase 3 ASCENT Study for Metastatic Triple-Negative Breast Cancer

August 11th 2021

Hope S. Rugo, MD, FASCO, discusses data presented at the 2021 American Society of Clinical Oncology annual meeting from the phase 3 ASCENT study of patients with metastatic triple-negative breast cancer treated with sacituzumab govitecan.

Future Directions for the Management of HR+ Breast Cancer

August 11th 2021

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

ES HR+ Breast Cancer: CDK4/6 Inhibitors in Clinical Practice

August 11th 2021

A discussion on the use of adjuvant CDK4/6 inhibitors in clinical practice for the treatment of early stage HR+ breast cancer.

Using CDK4/6 Inhibitors in Early Stage HR+ Breast Cancer

August 4th 2021

Experts in breast cancer share insights on the role of CDK4/6 inhibition in the adjuvant setting for early stage HR+ breast cancer.

Early Stage HR+ Breast Cancer: Optimizing Multigene Assays

August 4th 2021

Hope S. Rugo, MD, leads the discussion on the new data presented at the 2021 ASCO annual meeting for MammaPrint and Breast Cancer Index for early stage HR+ breast cancer.

Using Genomic Assays for Early Stage HR+ Breast Cancer

July 28th 2021

The role of genomic assays, including Oncotype DX as reported on in the RxPONDER trial, for the optimal management of early stage HR+ breast cancer is discussed.

Emerging Agents for the Management of HR+ mBC

July 28th 2021

Aditya Bardia, MD, MPH, leads the discussion on the use of novel CDK4/6 inhibitors, BCL2 inhibitors, and oral SERDS for the treatment of HR+ metastatic breast cancer.

PI3KCA Inhibition: Managing AEs in HR+ mBC

July 21st 2021

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, review the optimal management of adverse events associated with alpelisib in HR+ metastatic breast cancer.